Many more
Join
PharmEasy (API Holdings Ltd) Unlisted Shares
PharmEasy (API Holdings Ltd) Unlisted Shares
Sold Out
Pharma
*The above chart is presented for indicative purposes only and may not be accurate. The figures represented above are taken on an average basis, and may or may not match with the prevailing situation. Users are requested to not completely rely on the above chart and to consult an independent financial adviser and to take their investment decisions.
Overview
PharmEasy (API Holdings)
Overview of PharmEasy (API Holdings Ltd) Unlisted Shares
API Holdings holds the distinction of being India's largest digital healthcare platform based on the Gross Merchandise Value (GMV) of its products and services sold during the fiscal year ending on March 31, 2021.
Through its integrated and end-to-end business model, API Holdings leverages technology and fulfillment capabilities to solve the healthcare needs of consumers. PharmEasy operates under API Holdings Limited.
API’s objective of their tailor-made technology platform is to enable all stakeholders in the healthcare value-chain to reap the benefits of an interconnected network.
API collaborates closely with and develops services for various stakeholders in the healthcare value-chain, including consumers, pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors, clinics, and diagnostic labs. The Company’s expanding nationwide footprint, connected ecosystem approach, and multiple synergistic offerings, have enabled them to establish strong relationships with various stakeholders of the healthcare value chain.
PharmEasy (API Holdings) Unlisted Shares Price
Stay updated on the latest price of PharmEasy’s unlisted shares and Pharmeasy unlisted share price by visiting our website or downloading the TradeUnlisted app. Also, stay updated on API Holdings' share price and API Holdings' company share price by keeping track of the website. Get access to tentative prices, research reports, and other relevant information.
API Holdings’ Businesses & Brands
| Aknamed | Docon | PharmEasy | Retalio | Thyrocare |
| Tech-enabled Hospital Supplies Procurement | EMR and Practice Management Software for Clinics & Doctors | India’s Largest Online Pharmacy Marketplace | One of India’s Largest Pharma Platform connecting Pharmacies with Wholesalers | India's Largest Diagnostics Test Provider by Volumes |
Incorporated On
PharmEasy was founded by Mr. Dharmil Sheth and Dr. Dhaval Shah in 2014. In 2019, API Holdings Limited brought the company under its ambit.
Business Model
- PharmEasy provides medicine and medical accessory delivery services across various towns and cities in India. The pin codes are maintained by PharmEasy to determine the nearest pharmacies to the customers. Customers can place their orders through PharmEasy's website or mobile app.
- Ordering through the mobile app entitles customers to discounts of up to 20%, thereby enhancing brand recognition and attracting new customers.
- PharmEasy operates as an e-pharmacy with its processes primarily conducted online, functioning as a three-way channel between buyers, suppliers, and the distribution network.
Revenue Model
- PharmEasy's primary source of revenue is from sponsored results displayed on its website by various pharmaceutical companies.
- Advertising is a significant contributor to PharmEasy's revenue, with attractive discounts further boosting its revenue stream. These discounts make it more appealing than traditional pharmacies.
- PharmEasy provides additional discounts for payments made through its partner gateways and bank channels.
- Additionally, PharmEasy earns a commission from its customers for healthcare products and medicines sold through its platform.
- The brand also earns from delivery charges levied on its products.
PharmEasy Entrepreneur Network
- PharmEasy's Entrepreneur Network provides individuals with an opportunity to become a PharmEasy Franchise Partner for as little as INR 20,000/-.
- PharmEasy currently has over 800 franchise partners across the country.
- This expansion allows for mutual growth, as it enlarges the PharmEasy network while also enabling franchise partners to earn up to INR 1,00,000/- per month.
- Women franchise partners who generate sales exceeding INR 1 lakh per month receive an extra 1% commission on platform-only orders.
Major Takeaways of PharmEasy (API Holdings) Unlisted Shares
- Revenue - PharmEasy has nearly doubled its revenue in FY20 to INR 637 crore ($87.75 million)
- 5 Million+ Indian Families Serves
- 22,000+ Deliverable Pin-codes
- 1200+ Cities under the cover
- 80,000+ Pharmacy partners across the Country
- 10 Million+ App downloads so far
Recent Acquisitions by API Holdings
Medlife
- API Holdings Limited acquired Medlife, a major player in the e-pharmacy industry, in May 2021. As a result, the combined company has become the leading e-pharmacy in the country.
- Medlife is a healthcare company that focuses mainly on the wholesale and distribution of medicines.
- As of January 31, 2021, Medlife had a valuation of $375 million.
Thyrocare
- In June 2021, API Holdings Limited acquired a 66.1% stake in Thyrocare for INR 4,546 Cr, marking the first-ever acquisition of a listed company by an Indian unicorn
- Thyrocare Technologies Limited operates as a multinational chain of diagnostic and preventive care laboratories.
- It has a total of 1,122 outlets (as of 2021) and collection centers located throughout India and certain regions of Nepal, Bangladesh, and the Middle East.
- The combined entity has the ability to offer diagnostic and pharmacy services to 100 million people within 24 hours.
Aknamed
- API Holdings acquired Aknamed, India's largest cloud-based platform for hospital supply chain management, for approximately $180 to $190 million in September 2021.
- More than 1,200 hospitals, including Narayana Health, Manipal Hospitals, and Columbia Asia, utilize Aknamed's procurement solutions.
- By the end of FY21, Aknamed's monthly revenue run-rate had increased tenfold.
- This purchase, similar to its acquisition of Thyrocare, is part of API Holding's strategy to establish itself as a more comprehensive online healthcare company, expanding beyond being solely an online medicine delivery platform.
To stay updated on the share price of PharmEasy’s unlisted shares and PharmEasy stock price, visit our website or download the TradeUnlisted App. By doing so, you will be able to view estimated prices, access research reports, and other related information.
Download the TradeUnlisted App here: Android iOS
The story of PharmEasy (API Holdings)
2012 - 2014
The founders of API Holdings have been digital healthcare entrepreneurs since 2012, when they launched Dialhealth, a pharmaceutical delivery service for consumers in Mumbai. Dialhealth managed to collect demand citywide, but its ability to fulfill orders was hampered by supply chain complications. In an effort to gain better control over the supply chain, the founders established a pharmacy chain in Mumbai. Nonetheless, managing these pharmacies proved to be a challenge without full control over the supply chain. The founders shifted their focus from solely aggregating demand to aggregating both demand and supply. As a result, they created Ascent in 2013, a company that distributed pharmaceutical products to pharmacies.
2015 - 2016
The founders were impressed by Ascent's robust procurement and supply chain abilities in 2015, leading them to develop the technology that powers the PharmEasy marketplace. PharmEasy is a consumer healthcare super app, which enables the home delivery of pharmaceutical products to consumers as per their immediate requirements. The founders recognized that a comprehensive solution for the healthcare industry must address issues such as the lack of access to doctors, self-medication, and low digitization of prescriptions across the entire ecosystem. Consequently, they acquired Docon in 2016. Docon provides EMR and clinic management services, along with teleconsultation services catering to doctors, clinics, and patients alike.
2017 - 2020
Retailio, a digital platform, was launched by Ascent to boost technology adoption and expand supply capabilities beyond the pharmacies that Ascent served. Retailio's digitization has diminished the requirement for manual re-ordering cycles, resulting in more efficient inventory management, lower stock-outs, and improved expiry management for retailers.By December 2018, Ascent had emerged as one of the largest wholesalers of pharmaceutical products in India, based on the gross merchandise value (GMV) of products sold within the previous 12 months. Similarly, by December 2020, PharmEasy had established itself as the leading online pharmacy in India, in terms of the GMV of products sold within the previous 12 months.
2020
In August, all businesses established as part of this initiative were merged under API Holdings to form an integrated digital healthcare platform.
2021
In January, API Holdings acquired Medlife, which was one of India's top digital healthcare companies in terms of the gross merchandise value (GMV) of products sold on its platform in the financial year 2021, according to the RedSeer Report.
As per the report by RedSeer, API Holdings acquired Thyrocare in September 2021, which holds the position of India's largest player in diagnostics based on the volume of tests conducted. Similarly, API Holdings acquired Aknamed, in September, which is a prominent tech-enabled supplier of specialized medicines, pharmaceutical drugs, medical devices, surgical items, and other medical products to doctors and hospitals in India, as stated by Redseer. Furthermore, in October, API Holdings acquired a 49% interest in Marg, a leading ERP provider for distributors and retailers
Through these acquisitions, API's founders have expanded their reach to every stakeholder involved in healthcare, including consumers, doctors, laboratories, and hospitals.
Avail the latest price of PharmEasy (API Holdings) Unlisted Shares on the TradeUnlisted App. Download the TradeUnlisted App here: Android iOS
Summarizing PharmEasy (API Holdings) Unlisted Shares Key Investment Highlights
- The Indian e-pharmacy industry is relatively young and holds a huge potential for growth.
- The rapid digitalization of the pharmacy industry, alongside the emergence of inventive and user-friendly e-pharmacy platforms, has revolutionized a transformative shift in this sector.
- PharmEasy, being one of the leading players in the market, has secured a market share of approximately 60-70%, generating revenues of over INR 637 Cr in the fiscal year 2020.
- As the industry grows, PharmEasy with its sound business model and market domination, is expected to generate wealth to its stakeholders.
- The Company faces competition from other players such as Tata's 1MG, Apollo pharmacy, and Reliance's Netmeds operating in the same segment.
Key Management & Board of Directors
Siddharth Shah Co-Founder, Managing Director and Chief Executive Officer
Siddharth Shah serves as the Co-founder, Managing Director, and Chief Executive Officer of API Holdings. He earned a bachelor's degree in computer engineering from Dwarakadas J. Sanghavi College, Mumbai, and a post-graduate diploma in management from the Indian Institute of Management, Ahmedabad. Prior to this role, he was the managing director of Ascent Health and Wellness Solutions Private Limited.
Dharmil Sheth Co-Founder and Whole-time Director
Dharmil Sheth serves as a Co-founder and Whole-time Director of the Company. He completed his bachelor's degree in electronics engineering from K.J. Somaiya College of Engineering, University of Mumbai, and a post-graduate diploma degree in management (marketing) from Institute of Management Technology, Ghaziabad. Before this role, he worked with MakeMyTrip (India) Private Limited as a member of the online products team, and was also a director and co-founder of 91Streets Media Technologies Private Limited.
Dr. Dhaval Shah Co-Founder
Dhaval Shah is the Co-Founders of API Holdings. He possesses a post-graduate diploma in management from XLRI, Xavier School of Management, located in Jamshedpur, Jharkhand, in addition to an MBBS degree obtained from Maharashtra University of Health Sciences, located in Nashik. Prior to his current role, he worked as a consultant at McKinsey and Company Inc., and later as an executive director at 91Streets Media Technologies Private Limited.
Harsh Parekh Co-Founder and Whole-time Director : Harsh Parekh is a Co-founder and Whole-time Director of API Holdings. He obtained a master's degree in business administration from the School of Business Management, Narsee Monjee Institute of Management Studies, Mumbai. Prior to this role, he served as the Chief Operations Officer of Ascent Health and Wellness Solutions Private Limited. He has been a member of the Board of Directors since July 1, 2019.
Hardik Dedhia Co-Founder : Hardik Dedhia is a Co-Founder of the Company. On April 1, 2016, he joined Ascent Health and Wellness Solutions Private Limited as the Chief Technical Officer, which later merged into the Company pursuant to Merger 2020. He holds a bachelor's degree in electronics and telecommunication engineering from the University of Mumbai in Maharashtra, and a master's degree in electrical and computer engineering from Carnegie Mellon University located in Pennsylvania.
Aditya Puri Chairman, Non-Executive Director : Aditya Puri has been the Chairman and a Non-executive Director of API Holdings since April 2021. He is an associate member of the Institute of Chartered Accountants of India, New Delhi, and a chartered accountant. Before joining the Company, he served as the managing director of HDFC Bank Limited.
Deepak Vaidya Independent, Non-Executive Director : Deepak Vaidya has been serving as an Independent Director of the Company since April 2021. He is a chartered accountant and an associate member of the Institute of Chartered Accountants of India, New Delhi. In addition to his role at the Company, he is a board member of several companies operating in the pharmaceutical, hospitals, and finance sectors.
Ankur Thadani Non-Executive Director : Ankur Thadani has been a Non-Executive Director of the Company since March 2021. He earned his bachelor's degree in electronics and telecommunication engineering from the University of Mumbai, Maharashtra. Currently, he serves as a partner at TPG Growth and RISE Fund.
Ashutosh Sharma Non-Executive Director : Ashutosh Sharma has been serving as a Non-Executive Director of API Holdings since April 2021. He holds an MBA from the Booth School of Business, University of Chicago, Illinois. Prior to joining API, he had worked with Norwest Venture Partners and Qualcomm India Private Limited. Currently, he is associated with MIH Internet Private Limited, which is a part of Prosus, a global consumer internet group.
Vineeta Rai Independent, Non-Executive Director : Vineeta Rai has been an Independent Director of API Holdings since September 2021. She obtained her bachelor’s degree in arts (History Honors) from the University of Delhi, New Delhi. She is a retired Indian Administrative Officer (Batch of 1968) with vast experience in the areas of health administration and finance.
Dr. Jaydeep Tank Independent, Non-Executive Director : Jaydeep Tank joined the Company as an Independent Director in September 2021. He has a Doctor of Medicine degree (M.D.) with a specialization in Obstetrics and Gynaecology. He also holds a Diplomate of National Board (DNB) and a diploma in Gynecology and Obstetrics from the College of Physicians and Surgeons of Mumbai, Maharashtra.
Mr. Subramaniam Somasundaram Independent, Non-Executive Director : Subramaniam Somasundaram has been an Independent Director of API Holdings since September 2021. He earned a bachelor's degree in commerce from the University of Madras and is a chartered accountant and cost accountant with a background in finance, strategy, and business functions, including his previous role as CFO at Titan Company Limited. You can keep yourself informed about the current prices of unlisted PharmEasy shares by visiting our website or downloading the TradeUnlisted App. With the app, you can easily access up-to-date pricing information, read detailed research reports, and more.
Board Members
| Name | Designation |
|---|---|
| Mr. Siddharth Shah | MD & CEO |
| Mr. Aditya Puri | Chairman and Non-executive director |
| Mr. Harsh Parekh | Whole-time director |
| Mr. Dharmil Sheth | Whole-time director |
| Mr. Ashutosh Sharma | Non-executive director |
| Mr. Ankur Thadani | Non-executive director |
| Mr. Deepak Vaidya | Independent director |
| Ms. Vineeta Rai | Independent director |
| Mr. Subramaniam Somasundaram | Independent director |
| Mr. Ramakant Sharma | Independent director |
| Mr. Jaydeep Tank | Independent director |
Consolidated Results
Financial Highlights of last 2 years
(All figures INR in Cr except specifically mentioned)
| Particulars of the company | 2022 | 2021 |
|---|---|---|
| Total Revenue | 5728.82 | 2,335.27 |
| Profit before Tax (PBT) | -3970.77 | -620.26 |
| Profit After Tax (PAT) | -3992.50 | -644.83 |
| Earnings per share (EPS) (INR) | -7.28 | -2.67 |
Reports
Company Details
| Particulars | Details |
|---|---|
| Face Value (INR) | 1 |
| ISIN | INE0DJ201029 |
News
- PharmEasy parent API Holdings gets Sebi nod for Rs 6,250-cr IPO
- Exclusive | Aditya Puri joins board of PharmEasy’s parent API Holdings ahead of IPO
- API Holdings Unlisted Shares: Revolutionizing India's Healthcare Industry with PharmEasy and Beyond
- PharmEasy logs first ebitda profit of Rs 14 crore in April, restarts funding talks
- API Holdings Ltd (PharmEasy) Unlisted Shares | Pre-IPO
FAQs
The following is the process of buying PharmEasy (API Holdings Ltd) unlisted shares from the TradeUnlisted platform:
- Click on the ‘Invest now’ button on the PharmEasy page. The PharmEasy unlisted stocks will be added to your cart.
- In the cart section, you will be required to enter the quantity of PharmEasy unlisted shares you want to purchase.
- Next step is to select the payment method you wish to use. We accept payments via debit card, net banking and UPI.
- Payment must be made from the same account to which shares are to be transferred. Third party transactions are strictly prohibited on the platform.
- The TradeUnlisted team will contact you and set up the whole process smoothly.
- The shares will then be credited in the demat account mentioned in the CML copy within the timeline mentioned in the Deal Contract Letter.
In case you want to buy PharmEasy (API Holdings Ltd) unlisted shares offline, you may call us on +91 8958 212121 or write to us at [email protected].
The following is the process to sell unlisted shares on TradeUnlisted platform:
- Fill up the form on https://tradeunlisted.com/sell by choosing the Unlisted Stocks you wish to sell and enter the quantity of the shares along with an expected pricing for the shares.
- The TradeUnlisted team will contact you to confirm the deal.
- Once we confirm our buying price of the shares, we will share a copy of our Client Master List (CML).
- You will then be required to transfer the shares to our demat account.
- Once the shares are reflected in our demat account, we will transfer the funds to your bank account within the stipulated time and the same will be intimated to you.
- Payment will be made via RTGS, NEFT, IMPS, cheque or UPI. Payment will be made to the same account which is linked to your demat account.
In case you have any queries, you may call us on +91 8958 212121 or write to us at [email protected].
There is no restriction on transfer of unlisted shares until the IPO cut-off date which is generally a week before listing. However, after listing SEBI norms are applicable to these shares. As per SEBI regulations, all unlisted shares go in a lock-in period of 6 months from the date of listing of shares.
In case you have any queries, you may call us on +91 8958 212121 or write to us at [email protected]
If you sell the PharmEasy (API Holdings Ltd) unlisted shares within 2 years of its acquisition, then you will be required to pay tax on the short-term capital gain (STCG) as per the individual tax slab rate. Selling the shares after 2 years will attract a long-term capital gain (LTCG) which will be taxed at the rate of 20% with indexation benefit or 10% without indexation benefit.
Investors should consult with an independent third-party taxation advisor prior to making investment decisions.
In case you have any queries, you may call us on +91 8958 212121 or write to us at [email protected].
All unlisted shares can be transferred only to Demat accounts. Unlisted shares can be checked in two ways:
1. Option 1
- Download the NSDL or CDSL mobile application from the Google Play or App Store.
- Enter your DP ID + Client ID (total of 16 characters)
2. Option 2
You may also check the credit of your shares, by logging in to your Demat account and checking under DP Holdings in your respective DP.
In case you have any queries, you may call us on +91 8958 212121 or write to us at [email protected].
In the case of CDSL, the first 8 digits of your Demat Account Number are depository participant ID and the last 8 digits are your customer ID with the depository participant. The same goes for NSDL where ‘IN’, the 6 digits are depository participant ID and the rest of the numbers reflect your customer ID with a depository participant.
National Securities Depository Limited (NSDL): The Demat account number of NSDL starts with alphabets ‘IN’ followed by 14 numeric digits.
For e.g. IN30000012345678.
Central Depository Service Limited (CDSL) : The entire DEMAT account number of CDSL is numeric.
For e.g.1234567800001234
In case you have any queries, you may call us on +91 8958 212121 or write to us at [email protected].
The PharmEasy unlisted shares are credited in your Demat account within a maximum of two (working) days after the funds are received in our bank account. However, please note that at times there may be a slight delay in the credit of shares due to certain reasons like Bank Holidays.
In case you have any queries, you may call us on +91 8958 212121 or write to us at [email protected].
Investments on TradeUnlisted start from as low as INR 5,000. Please call us on +91 8958 212121 to find the company specific details pertaining to the lot size and minimum investment amount.
To track news and other information of PharmEasy (API Holdings Ltd) unlisted shares, you can join our Telegram Channel or Facebook Community to stay updated on all news of the unlisted space.
You can track prices and access historical graphs of Unlisted Shares on both our website and mobile application.
Download our mobile App from the Google Play or App Store.
The financials are available in the Research Report, DRHP, and Annual Reports of PharmEasy (API Holdings Ltd) Unlisted Shares, which may be found under the Reports section of the company's specific page. You can download all the reports after logging in.
